A recent study has unveiled that GLP-1 medications, such as Ozempic and Wegovy, might significantly reduce the risk of certain cancers. This revelation is particularly compelling given the established link between excess weight and an elevated cancer risk. According to the Centers for Disease Control and Prevention (CDC), about 40% of new cancer diagnoses are related to excess weight. In 2021 alone, the CDC reported approximately 170 new cancer diagnoses per 100,000 people. The study, published in the journal JAMA Network Open, provides promising insights into the potential benefits of GLP-1 drugs beyond their known applications in weight loss and diabetes management.
Cancer Risk and Obesity
Obesity is a major risk factor for 13 types of cancer. The CDC emphasizes that the longer an individual is overweight and the more weight they gain, the higher their cancer risk becomes. Obesity can lead to chronic inflammation, elevated insulin levels, and an increase in insulin-like growth factors and sex hormones, all of which can contribute to cancer development. This underscores the importance of weight management in cancer prevention strategies.
GLP-1 Medications and Cancer Risk Reduction
The recent study focused on individuals with type 2 diabetes, revealing that those treated with GLP-1 drugs had a significantly lower incidence of 10 out of the 13 obesity-associated cancers compared to those treated with insulin. Specifically, the risk of developing gallbladder cancer, meningioma, pancreatic cancer, and hepatocellular carcinoma (a type of liver cancer) was more than halved. The study also noted a substantial reduction in the risk for ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer, and kidney cancer among GLP-1 users.
Also Read: Nearly Half Of Adult Cancer Deaths In The US Could Be Prevented By Making Lifestyle Changes: Study
Mechanisms Behind the Reduced Risk
GLP-1 medications interact with the body’s insulin production systems, which might explain their role in reducing cancer risk. These drugs can potentially mitigate the adverse effects of high insulin and insulin-like growth factor levels, both of which are linked to cancer development. Additionally, GLP-1 drugs have been associated with other beneficial effects similar to those observed with intensive lifestyle interventions and metabolic-bariatric surgery, both of which have been shown to reduce cancer risk in previous studies.
Exceptions and Considerations
Despite the promising findings, the study highlighted that GLP-1 treatments did not reduce the risk of postmenopausal breast cancer, the most common cancer associated with obesity according to the CDC. Moreover, no significant risk reduction was observed for stomach or thyroid cancers. In fact, other research suggests that GLP-1 drugs might interact with insulin production in ways that could negatively impact the thyroid. This underscores the need for patients to be aware of potential thyroid-related risks, which are indicated on the medication packaging.
Also Read: New HIV Prevention Drug Offers Total Protection To Young Women: Study
Comparison with Metformin
Interestingly, the study found no significant difference in overall cancer risk between those treated with GLP-1 medications and those treated with metformin, another common diabetes drug. However, the risk of kidney cancer was found to be higher in individuals using GLP-1 drugs compared to those on metformin. This finding indicates that while GLP-1 medications offer substantial benefits, they are not without potential risks, and their effects can vary depending on the type of cancer.
Study Scope and Future Research
The study analyzed over a decade of medical records for nearly 1.7 million individuals with type 2 diabetes, providing a robust dataset for evaluating the long-term effects of GLP-1 drugs. Despite these promising findings, the study authors emphasized the need for more research to understand how reduced cancer risk relates to the extent of weight loss. They advocate for further preclinical and clinical studies to explore the potential of GLP-1 receptor agonists (GLP-1RAs) in cancer prevention, especially in high-risk populations.
Bottomline
The findings of this study offer a glimmer of hope in the fight against cancer, particularly for those struggling with obesity and type 2 diabetes. GLP-1 medications, already known for their efficacy in weight loss and diabetes management, now show potential in reducing the risk of several obesity-related cancers. As research continues, these medications might become an integral part of cancer prevention strategies, offering a multifaceted approach to improving public health outcomes.